Literature DB >> 6583197

Susceptibility of anaerobic bacteria to imipenem.

F P Tally, N V Jacobus.   

Abstract

The in vitro susceptibility of 157 anaerobic bacteria to imipenem was compared with that to cefoxitin, latamoxef (moxalactam) and clindamycin. The isolates were cultured from clinical specimens submitted to Tufts Anaerobic Laboratory between January 1981 and March 1983. Two strains of Bacteroides fragilis only, were highly resistant to imipenem. The incidence of cefoxitin resistance in the Bact. fragilis group has increased at Tufts-New England Medical Center. The data indicate that imipenem is the most active beta-lactam drug against anaerobic bacteria, including Bact. fragilis group of organisms. The only difference, since our original studies with thienamycin, is the recognition of two imipenem-resistant strains of Bact. fragilis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6583197     DOI: 10.1093/jac/12.suppl_d.47

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.

Authors:  H C Neu; N X Chin; G Saha; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

2.  Imipenem/cilastatin.

Authors:  M Barza
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 3.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

4.  Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content.

Authors:  I Podglajen; J Breuil; I Casin; E Collatz
Journal:  J Bacteriol       Date:  1995-09       Impact factor: 3.490

5.  In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria.

Authors:  S D Shafran; J Wong; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

Review 6.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

7.  Pharmacokinetics of imipenem-cilastatin in neonates.

Authors:  B J Freij; G H McCracken; K D Olsen; N Threlkeld
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.

Authors:  C Betriu; C Cabronero; M Gomez; J J Picazo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

9.  Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections.

Authors:  W Fan; R del Busto; M Love; N Markowitz; C Cendrowski; J Cardenas; E Quinn; L Saravolatz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Susceptibility of anaerobic bacteria from several French hospitals to three major antibiotics.

Authors:  L Dubreuil; J Devos; C Neut; C Romond
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.